RenovaCare SkinGun™ Stem Cell Sprayer on Exhibit at the Science Museum in London
RenovaCare, Inc. today announced the first-ever public display of its breakthrough technology, on exhibit now at the UK’s prestigious Science Museum in London.
RenovaCare Announces Successful Closing of Financing
RenovaCare, Inc. today announced the closing of its previously announced registered direct offering of 915,000 shares of its common stock at a an offering price of $2.50 per share and its concurrent private placement of common stock purchase warrants (the “Warrants”) to purchase…
RenovaCare, Inc. Closes Registered Direct Offering and Concurrent Private Placement
RenovaCare, Inc. today announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately 915,000 shares of common stock in a registered direct offering and common stock purchase warrants in a concurrent private placement…
Peer-Reviewed Publication Validates RenovaCare Approach to Rapidly-Processing Stem Cells for Burns and Wounds
RenovaCare, Inc. has announced that its approach to isolating a patient’s own stem cells for subsequent spray onto burns and wounds has been validated by researchers in ‘Differentiation’, a leading peer-reviewed scientific publication. According to their findings, the methodology, which has been…
Outcomes of Burn Patients Treated with Cell Spray Technology Behind RenovaCare SkinGun™ Published in Prestigious Medical Journal
RenovaCare highlighted an analysis of treatment results on a variety of wide-area and severe burn injuries published in Burns, the peer-reviewed Journal of the International Society for Burn Injuries. The treatment method, which involved isolating and spraying the patient’s own skin stem cells on the burn wounds…
RenovaCare: 2017 Shareholder Update
Thanks to your support, 2016 was an incredible year for us and our CellMist™ and SkinGun™ technologies for spraying a patient’s own stem cells on to wounds and burns. We closed the year emboldened by the issuance of an important new patent…
RenovaCare Awarded U.S. Patent For SkinGun™ Device To Spray Stem Cells On To Wounds
RenovaCare, Inc., announced that the company has bolstered its patent portfolio with the issuance of a United States patent for its novel SkinGun™ device. The United States Patent and Trademark Office has granted an additional 30-month extension for the patent, providing protection beyond the year 2035.
Scientific Expert, Dr. Roger Esteban-Vives, Joins RenovaCare to Advance its SkinGunTM Technology for Spraying Stem Cells onto Burns
RenovaCare, Inc., announced the appointment of Roger Esteban-Vives, Ph.D. as Director of Cell Sciences.
Latest Test Results Bolster RenovaCare Strategy to Spray Stem Cells on Wounds and Burns for Rapid Healing
RenovaCare, Inc., today announced positive spray test results demonstrating that its novel SkinGun™ technology achieves exceptionally-uniform distribution of fluids with 200 times greater coverage than conventional methods. These outcomes are especially promising to scientists developing patented RenovaCare CellMist™ and SkinGun™ technologies* for spraying fluids containing a patient’s own stem cells onto burns and wounds for rapid scar-free healing.
New Study: RenovaCare SkinGun™ Ultra-Gently Sprays Human Stem Cells to Achieve ‘Gold-Standard’ Viability for Skin Regeneration
New York & Pittsburgh – May 3, 2016 – RenovaCare, Inc., (OTCQB: RCAR), a developer of novel medical grade liquid spray devices and patented CellMist™ and SkinGun™ technologies*, today announced favorable outcomes from laboratory studies conducted by Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité – Universitätsmedizin Berlin, one of the…